Description | DorsomorphindihydrochlorideisapotentandselectiveAMPKinhibitor,thatiscompetitivewithATP,withKiof109±16nMintheabsenceofAMP. |
---|---|
IC50&Target | Ki:109±16nM(AMPK)[1] |
InVitro | HT1080cellsaretreatedwith10μMDorsomorphinfor2hunder2DGstress.ImmunoblotanalysisrevealsthatphosphorylationlevelsofthecatalyticαsubunitofAMPKareincreasedbyexposureofHT1080cellsto2DG,whereasbothbasaland2DG-inducedphosphorylationlevelsareclearlyreducedwhenDorsomorphinisadded.MeasurementsofcellularkinaseactivityusinganELISA-basedassaysystemconfirmedthatDorsomorphindoesreducetheendogenousAMPKactivityregardlessofcellcultureconditions[2]. |
InVivo | AdmiNISTrationofDorsomorphinover24hleadstoa60%increaseintotalserumironconcentrations.Dorsomorphintreatmentisthereforeeffectiveinreducingbasallevelsofhepcidinexpressionandincreasingserumironconcentrationsinadultmice[3]. |
References |
|
PreparingStockSolutions |
Pleaserefertothesolubilityinformationtoselecttheappropriatesolvent. | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
KinaseAssay [2] | HT1080cellsareseededin24-wellplates(2×104cellsperwell)andtreatedwithDorsomorphininthepresenceorabsenceofglucoseor10mM2DGfor2h.HT1080cellsthatoverexpressedthewild-typeanddominantnegativeAMPKα1arepreparedbytransfectingplasmidDNA(pAMPKα1-wt,pAMPKα1-D168AandpcFlagasacontrol)in6-wellplates,seedingin24-wellplateandtreatingwithUPRinhibitors.Cellsarelysedwithcelllysisbuffer(20mMTris-HCl,pH7.5,250mMNaCl,10%glycerol,0.5%NP-40,1mMEDTA,1mMEGTA,0.2mMPMSF,1μg/mLpepstatin,0.5μg/mLleupeptin,5mMNaF,2mMNa3Vo4,2mMβ-glycerophosphate,1mMDTT).RelativeAMPKkinaseactivity(mean±SDofduplicatedeterminations)tocontrolsample(vehicleorpcFlagundernormalgrowthconditions)isdeterminedusingtheCycLexAMPKkinaseassaykit[2].MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly. | ||||||||||||||||
CellAssay [2] | DorsomorphinisdissolvedinDMSO(10mM)andstored,andthendilutedwithappropriatemedia(DMSO0.5%)beforeuse[2]. HeLaand786-OcellsaretreatedwithvariousconcentrationsofDorsomorphin(0,0.3,1,3,10μM),VersipelostatinandPhenformininthepresenceorabsenceof10mM2DGor1μg/mLofTunicamycinasastressorfor30hin96-wellplates.Forthecombinationstudy,786-OcellsaretreatedwithvariousconcentrationsofUPRinhibitorsinthepresenceorabsenceof10mM2DGfor24h.Themediumisthenreplacedwithfreshgrowthmedium,andcellsareculturedforafurther15h.Subsequently,MTTisaddedtotheculturemedium,andtheabsorbanceofeachwellisdetermined.FortheviABIlityassayunderglucose-withdrawalconditions,HT1080cellsaretreatedwithvariousconcentrationsofDorsomorphinandphenforminin12-wellplatesinthepresenceorabsenceofglucosefor18h,seededin96-wellplateswithgrowthmedium,andthenculturedforafurther48hbeforeMTTisadded.Relativecellsurvival(mean±SDofquadruplicatedeterminations)iscalculatedbysettingeachcontrolabsorbancefromuntreatedcellsas100%.Theeffectsofdrugcombinationsatconcentrationsproducing80%cellgrowthinhibition(IC80)areanalyzedusingtheisobologrammethod[2].MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly. | ||||||||||||||||
AnimalAdministration [3] | DorsomorphinispreparedasastocksolutioninDMSO[3]. Mice[3] | ||||||||||||||||
References |
|
MolecularWeight | 472.41 | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Formula | C₂₄H₂₇Cl₂N₅O | ||||||||||||
CASNo. | 1219168-18-9 | ||||||||||||
Storage |
| ||||||||||||
Shipping | RoomtemperatureincontinentalUS;mayvaryelsewhere | ||||||||||||
Solvent&Solubility | H2O:≥48mg/mL;DMSO:5.2mg/mL(Needultrasonic) Dorsomorphindihydrochlorideisdissolvedinsaline[4]. *"<1 mg/ml"="" means="" slightly="" soluble="" or="" insoluble.="" "≥"="" means="" soluble,="" but="" saturation="">1> | ||||||||||||
References |
|
Purity:99.73%